Premier Alternatives

Parallel Bio

Drug Discovery · Cambridge, MA · Founded 2020 · Privately Held (backing)

Operator of a biotechnology company intended to design and engineer tools to change the way diseases are cured. Parallel Bio is based in Cambridge, MA and was founded in 2020. It was valued at $71.5 million at its later-stage round in Jun 2025, the last priced event on record. It has raised $24.6 million across 2 recorded rounds; the latest was a $20 million Series A1 in Jun 2025.

PMV mark · valuation
$71.5M
Oct 2026
Priced at
its later-stage round
Jun 2025
Total raised
$24.6M
Last round
Later Stage VC (Series A1)
Jun 2025

Parallel Bio key facts

as of Oct 2026
  • Operator of a biotechnology company intended to design and engineer tools to change the way diseases are cured.
  • Parallel Bio is valued at approximately $71.5M as of Oct 2026, set at its later-stage round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $24.6M across 2 recorded rounds; the latest was Later Stage VC (Series A1) ($20.0M) in Jun 2025.
  • Notable investors include Y Combinator, Gaingels, Metaplanet Holdings, Asymmetry Ventures, Jeff Dean — 24 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$71.5M

Valued at $71.5M at its later-stage round, Jun 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Parallel Bio with a free account
  • ·The complete investor list: 24 names
  • ·Watch Parallel Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Parallel Bio funding rounds

2 rounds
Jun 2025Later Stage VC (Series A1)$20.0M▮
Dec 2022Seed Round$4.3M▮
Full funding history →

Parallel Bio valuation

Parallel Bio was valued at $71.5 million at its later-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Parallel Bio raised?

Parallel Bio has raised $24.6 million across 2 recorded rounds since 2022. The largest was a $4.3 million seed round in Dec 2022; the most recent was a $20 million Series A1 in Jun 2025.

Parallel Bio investors

24 investors are on record for Parallel Bio, including Y Combinator, Gaingels, Metaplanet Holdings and Asymmetry Ventures. By type, the record holds 7 venture capital firms and 1 family office. The Series A1 in Jun 2025 drew 7 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Hyku Biosciences ($85 million), Linnaeus Therapeutics ($83.1 million) and Pangea Bio ($80 million).

About Parallel Bio

Operator of a biotechnology company intended to design and engineer tools to change the way diseases are cured. The company's platform deploys human immune organoids to rapidly accelerate the discovery and development of immunotherapies, cell therapies, antibody therapies, and vaccines, enabling medical professionals to have access to novel insights into human biology.

Industry
Drug Discovery
Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2020
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.